Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Geometric mean titers of serum neutralizing antibodies to vaccine included HPV types (16/18/6/11) at 7, 12, 24, 36, 48 months.
5 years from the base-line date
Rengaswamy Sankaranarayanan, MD
International Agency for Research on Cancer
India: Drugs Controller General of India